Want to see IN:BLISSGVS full AI Analyst Report?
BLISSGVS Stock Chart & Stats
₹144.75
-₹6.85(-3.92%)
At close: 4:00 PM EST
₹144.75
-₹6.85(-3.92%)
Day’s Range― - ―
52-Week Range₹118.35 - ₹552.90
Previous CloseN/A
Volume571.01K
Average Volume (3M)104.36K
Market Cap
₹49.57B
Enterprise Value₹50.10B
Total Cash (Recent Filing)₹1.89B
Total Debt (Recent Filing)₹217.50M
Price to Earnings (P/E)38.4
Beta1.24
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.32%
Share Statistics
EPS (TTM)12.13
Shares Outstanding106,056,220
10 Day Avg. Volume77,644
30 Day Avg. Volume104,358
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)2.03
Price to Sales (P/S)2.61
P/FCF Ratio29.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow and declining debt with rising equity/assets provides durable financial flexibility. This reduces refinancing risk, supports capital spending for manufacturing or approvals, and allows the company to absorb demand volatility in export markets while maintaining operations over the next several months.
Improved Cash GenerationA sharp rebound to positive operating and free cash flow shows the company's ability to restore cash generation after a weak year. Sustained FCF supports internal funding of capex, regulatory/compliance spend, and debt reduction, increasing resilience and optionality over a 2–6 month horizon.
Diversified Market Exposure And Steady RevenuesA business model selling finished dosages domestically and into regulated/semi-regulated export markets provides diversified revenue streams and reduces single-market concentration. Combined with steady revenue growth history, this supports more predictable demand and scale benefits across medium-term planning cycles.
Bears Say
Volatile Margins And EarningsHistorically volatile margins and earnings reduce earnings predictability and complicate multi-period planning. For a specialty/generic pharma player, margin swings imply exposure to pricing pressure, product-mix shifts, or one-offs, making assessment of sustainable profitability harder over coming months.
Choppy Cash ConversionLarge swings in free cash flow and prior negative FCF indicate working-capital or timing variability. Such inconsistency can constrain reinvestment, raise short-term liquidity pressure during order or receivables cycles, and limit predictable funding for approvals or capacity expansion.
Operating-profit Clarity IssuesAn atypical EBITDA versus EBIT relationship and limited margin disclosure reduce transparency on core operating performance. This opacity makes it harder to distinguish recurring margins from non-operating items or one-offs, complicating forecasts of sustainable earnings and margin durability.
Bliss Gvs Pharma Limited News
BLISSGVS FAQ
What was Bliss Gvs Pharma Limited’s price range in the past 12 months?
Bliss Gvs Pharma Limited lowest stock price was ₹118.35 and its highest was ₹552.90 in the past 12 months.
What is Bliss Gvs Pharma Limited’s market cap?
Bliss Gvs Pharma Limited’s market cap is ₹49.57B.
When is Bliss Gvs Pharma Limited’s upcoming earnings report date?
Bliss Gvs Pharma Limited’s upcoming earnings report date is Aug 04, 2026 which is today.
How were Bliss Gvs Pharma Limited’s earnings last quarter?
Bliss Gvs Pharma Limited released its earnings results on May 12, 2026. The company reported ₹3.363 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.363.
Is Bliss Gvs Pharma Limited overvalued?
According to Wall Street analysts Bliss Gvs Pharma Limited’s price is currently Overvalued.
Does Bliss Gvs Pharma Limited pay dividends?
Bliss Gvs Pharma Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.32%. See more information on Bliss Gvs Pharma Limited dividends here
What is Bliss Gvs Pharma Limited’s EPS estimate?
Bliss Gvs Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bliss Gvs Pharma Limited have?
Bliss Gvs Pharma Limited has 106,056,220 shares outstanding.
What happened to Bliss Gvs Pharma Limited’s price movement after its last earnings report?
Bliss Gvs Pharma Limited reported an EPS of ₹3.363 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.59%.
Which hedge fund is a major shareholder of Bliss Gvs Pharma Limited?
Currently, no hedge funds are holding shares in IN:BLISSGVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bliss Gvs Pharma Limited
Established in 1984 and headquartered in Mumbai, India, Bliss GVS Pharma Limited specializes in the development, manufacturing, and distribution of a comprehensive array of pharmaceutical products. The company's pharmaceutical portfolio includes an extensive range of dosage forms, such as oral solids (tablets, capsules), various liquid and injectable preparations, topical applications (creams, gels), and advanced drug delivery systems like transdermal patches. Beyond conventional medicines, Bliss GVS also offers a diverse selection of other healthcare and personal care items, including balms, lotions, shampoos, and over-the-counter remedies. Their therapeutic focus is equally broad, encompassing solutions for anti-infectives, pain management, gastrointestinal issues, anti-malarials, dermatological conditions, nutritional support, and a wide variety of other wellness and hygiene products, including medicated and cosmetic soaps. The company actively engages in international exports, extending its market presence beyond India.
Technical Analysis
Innova Captab Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Orchid Pharma Limited
―
RPG Life Sciences Limited
―
Unichem Laboratories Limited
―